Medical Condition News

RSS

Ivabradine reduces heart volume among patients with cardiac insufficiency

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Universit- de Montr-al, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.

30 Aug 2011

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.

30 Aug 2011

U-M offers transplantation for patients with bile duct cancer

Robert "Buzz" Gehle thought the itchy rash he was experiencing was a recurrence of an earlier case of shingles. But when his doctor saw he was also jaundiced, he immediately knew there was a problem with Gehle's liver.

30 Aug 2011

Optical treatment strategies to correct peripheral vision may slow progression of myopia

New scientific evidence on how feedback from the eye affects visual development may lead to more effective approaches to treating myopia (nearsightedness) in children, reports a paper in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

29 Aug 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

Zymeworks, Merck collaborate to develop novel bi-specific antibody therapeutic candidates

Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.

29 Aug 2011

New insights into Lafora disease

Short-term energy storage in animal cells is usually achieved through the accumulation of glucose, in the form of long and branched chains, known as glycogen. But when this accumulation happens in neurons it is fatal, causing them to degenerate. This neuronal deterioration and death associated with glycogen accumulation is the hallmark of an extremely rare and progressive type of epilepsy known as Lafora disease (LD).

29 Aug 2011

Bioness announces commercial release of NESS L300 Plus System

Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.

29 Aug 2011

Post myocardial infarction snus quitters have 44% lower risk of mortality

In this prospective cohort study, presented today at the ESC Congress 2011, discontinuation of smokeless tobacco after a myocardial infarction (MI) is associated with a lower risk of subsequent mortality. Investigators found that post MI snus quitters had a 44 % lower risk of total mortality.

29 Aug 2011

Men worse than women at protecting their skin in the sun

Nearly 90 per cent of British adults admit their skin has been sunburnt - with almost half experiencing pain as result of being in the sun.

29 Aug 2011

BIOTRONIK's Selectra left ventricular lead delivery system receives European market approval

BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.

29 Aug 2011

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction of cardiovascular events.

29 Aug 2011

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

A specific inhibitor of the small regulatory RNA-molecule "microRNA-100" can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded.

29 Aug 2011

U-M's minimally invasive revascularization procedure can treat peripheral arterial disease

Henry Gibbs, 58, is a ballroom dance instructor, but he was forced to hang up his dancing shoes when a circulation condition, common among older adults, caused severe leg pain and cramping.

29 Aug 2011

UCLA-Harvard medication study highlights 3 types of confusing outcome measures

Studies about medications published in the most influential medical journals are frequently designed in a way that yields misleading or confusing results, new research suggests.

29 Aug 2011

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR), has signed an exclusive license with Amorfix Life Sciences Ltd. of Missisauga, Ontario for the use of their proprietary ProMIS technology in developing vaccines (active immunotherapy) for the treatment of diseases caused by the formation of misfolded prion.

29 Aug 2011

Low-glycemic foods, high protein intake reduce body weight and fat mass

A new study out of Madrid, Spain shows that low-glycemic foods, and moderately high-protein intake has been shown to reduce body weight and fat mass.

29 Aug 2011

Philips to launch first sleep apnea mobile app at ESC 2011 congress

Royal Philips Electronics will provide clinicians from across the globe with a glimpse of future innovations designed to advance cardiac care, including the current management of cardiovascular disease (CVD) and associated cardiac conditions, during the 2011 Congress of the European Society of Cardiology (ESC), which opens today in Paris.

From Philips Healthcare 29 Aug 2011

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

Hollywood, Health & Society, a program of the Norman Lear Center at the University of Southern California (USC) Annenberg School for Communication & Journalism and the Centers for Disease Control and Prevention (CDC), are announcing eight finalists for the Sentinel for Health Awards.

29 Aug 2011

Medical Condition News

Ivabradine reduces heart volume among patients with cardiac insufficiency

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

U-M offers transplantation for patients with bile duct cancer

Optical treatment strategies to correct peripheral vision may slow progression of myopia

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Zymeworks, Merck collaborate to develop novel bi-specific antibody therapeutic candidates

New insights into Lafora disease

Bioness announces commercial release of NESS L300 Plus System

Post myocardial infarction snus quitters have 44% lower risk of mortality

Men worse than women at protecting their skin in the sun

BIOTRONIK's Selectra left ventricular lead delivery system receives European market approval

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

U-M's minimally invasive revascularization procedure can treat peripheral arterial disease

UCLA-Harvard medication study highlights 3 types of confusing outcome measures

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

Low-glycemic foods, high protein intake reduce body weight and fat mass

Philips to launch first sleep apnea mobile app at ESC 2011 congress

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News